Impurity deficiencies in submissions are remarkably consistent. Subathra Ramamoorthy, Veranova, explains how to catch them before agency filing.
|Articles|January 24, 2017
Aptar Pharma launches eDose Counter for MDIs integrating a proprietary sensing technology
Author(s)Aptar
Aptar Pharma will showcase eDose Counter for MDIs integrating a proprietary sensing technology, at the Pharmapack Europe conference to be held in Paris, France on February 1-2, 2017
Advertisement
eDose Counter for MDIs
Picture courtesy of Aptar Pharma
Aptar Pharma will showcase eDose Counter for MDIs integrating a proprietary sensing technology, at the Pharmapack Europe conference to be held in Paris, France on February 1-2, 2017
Aptar Pharma – Booth N° F7
Aptar Pharma unveils its eDose Counter for metered dose inhalers (MDIs). Our patented eDose Counter for MDIs is designed to be easy-to-use and reliable, and contributes to patient compliance. Our unique sensing technology offers direct detection of the spray, which eliminates risks of miscounting. The sensing technology is versatile and compatible with any metering valve design. In addition, our eDose Counter for MDIs includes inhaler priming and medication reminders-to-use and end-of-product-life warnings (flashing digits) while remaining cost-effective.
For further information, visit
About Aptar Pharma
Aptar Pharma is part of the AptarGroup family of companies, along with Aptar Beauty + Home and Aptar Food + Beverage.
AptarGroup, Inc. is a leading global supplier of a broad range of innovative dispensing solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food, and beverage markets.
AptarGroup is headquarters in Crystal Lake, Illinois, with manufacturing facilities in North America, Europe, Asia and South America. To learn more, visit www.aptar.com/pharma
Advertisement
Related to this article
Subathra Ramamoorthy, Veranova, on how forced degradation and trace impurity profiling in potent APIs shape regulator-ready analytical methods.
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Improving Oral Peptide Delivery Through Structural Modifications
2
Using OEE Monitoring to Justify Expenditure on Aging Production Lines
3
Regulatory Roundup—October 2026: FDA Advances Rare Disease Development and Transparency Efforts
4
RRP Accelerated Approval: What VOCERYQ Means for Manufacturing Teams
5